This is a biotech Stock, Its a long term process.

This is a biotech Stock, Its a long term process. Propanc has a viable product in PRP that is moving ahead with great results.

Let me break the process down:
First there is the animal testing, which PPCH has shown great results.
Second, PPCH had to raise money to do the human trials, which they have done. In doing so PPCH has enough to get through to the end of the year to start the trails. They are doing everything to ensure that they are ready for human trials.
Past is not promise for the future but when a Biotech company announces they are in Phase I or II trials, that when you will see a pop in the stock price

The information provided above came to you from Uptick Newswire (herein referred to as “us”, “we” or “the website”) is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. All information that we provide is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Furthermore, investing in such securities involves substantial risk of loss and investors should seek advice from financial professionals before investing.

Uptick Newswire provides social media outreach and Investor Relations services for Micro-Cap companies. These are paid services. We may from time to time hold shares of companies featured as payment for services rendered. It is understood that Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that the investor’s entire investment may be lost or impaired due to the speculative nature of the companies listed.

Uptick Newswire makes no recommendation that the securities of the companies listed should be purchased, sold or held by individuals or entities that learn of the listed companies through Uptick Newswire representatives or upticknewswire.com. Any suggestions made by Uptick Newswire staff regarding companies featured on upticknewswire.com is solely that “a suggestion” nothing more. It is our expectation that investors will do their own due diligence.
We recommend that readers use the information found within as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. Uptick Newswire is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.